Status:

RECRUITING

Effects of UNICLA-A2 Dairy Products on Patients At High-risk of Colorectal Cancer Development

Lead Sponsor:

Instituto de Investigación Sanitaria Aragón

Collaborating Sponsors:

Cooperativas Lacteas Unidas

Hospital Clínico Universitario Lozano Blesa

Conditions:

Colorectal Polyp

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce i...

Detailed Description

Colorectal cancer (CRC) is one of the most frequent cancers in the world and has a significant impact in terms of mortality and health costs. It is estimated that CRC causes around 900,000 deaths annu...

Eligibility Criteria

Inclusion

  • Participants diagnosed with high-risk polyps in the colorectal cancer screening programme or in the relative's colon cancer prevention program or patients who are in follow-up due to prior detection of polyps with any of the following characteristics:
  • At least 10 adenomas
  • At least 5 proximal serrated polyps (PSP)
  • At least 2 serrated polyps with diameters ≥10 mm
  • Serrated Polyposis Syndrome (SPS)
  • Early invasive CRC (stage pT1) endoscopically resected (surgery not required)
  • A sessile or flat lesion ≥ 20 mm with fragmented resection
  • Patients with previous resection of polyps in which the resection margin was not assessable and are considered susceptible to repeat colonoscopy
  • Patients with intramucosal carcinoma in situ or invasion of the lamina propria (pTis)
  • Regular consumer of milk and dairy products.
  • Informed consent form signed.

Exclusion

  • History of allergic reaction attributed to compounds of similar chemical composition to the study agents.
  • Incomplete colonoscopy or with poor quality criteria, Boston \<6.
  • Concomitant acetylsalicylic acid (ASA), NSAIDs, misoprostol, corticosteroids or statins needed on a regular or predictable basis during the time of the study.
  • Previous gastrointestinal surgery (colon or small intestine or gastric) that affects the absorption of nutrients.
  • History of familial adenomatous polyposis.

Key Trial Info

Start Date :

February 28 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 15 2026

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT04824053

Start Date

February 28 2022

End Date

December 15 2026

Last Update

February 27 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Angel Lanas Arbeloa

Zaragoza, Zaragoza, Spain, 50009

Effects of UNICLA-A2 Dairy Products on Patients At High-risk of Colorectal Cancer Development | DecenTrialz